On March 29, AstraZeneca announced that its oral complement factor D inhibitor, Voydeya (danicopan), has received approval from the U.S. FDA as an adjunct therapy for adults with PNH who are experiencing extravascular hemolysis (EVH), intended for use alongside C5-targeted monoclonal antibodies [60]. This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.